ArticleObesity surgery2020
A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals.
Article in Obesity surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Post-bariatric hypoglycaemia: from altered gut physiology to targeted therapies.Endocrine connections · 2026Article
- Post-bariatric Hypoglycemia Management: A Gulf Cooperation Council Consensus Statement.Journal of the Endocrine Society · 2026Article
- Clip-Based Endoscopic Anastomotic Reduction in Patients with Dumping Syndrome and Postbariatric Hypoglycemia after Roux-en-Y Gastric Bypass.Endoscopy international open · 2026Article
- Managing post-bariatric hypoglycemia: a systematic review of pharmacological therapies.Diabetology & metabolic syndrome · 2025Article
- Postprandial hypoglycemia as a complication of bariatric and metabolic surgery: a comprehensive review of literature.Frontiers in surgery · 2024Review
- Hypoglycemia post bariatric surgery: drugs with different mechanisms of action to treat a unique disorder.Archives of endocrinology and metabolism · 2023Review
- Pasireotide-a novel somatostatin receptor ligand after 20 years of use.Reviews in endocrine & metabolic disorders · 2022Review
- Pramlintide for post-bariatric hypoglycaemia.Diabetes, obesity & metabolism · 2022Article
- Patient involvement to inform the design of a clinical trial in postbariatric hypoglycaemia.BMC medical research methodology · 2020Article
- Hypoglycemia After Upper Gastrointestinal Surgery: Clinical Approach to Assessment, Diagnosis, and Treatment.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Review
- Diagnosis and Management of Post-Bariatric Hypoglycemia.Journal of the American Board of Family Medicine : JABFMReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 μg, 150 μg, and 300 μg) on the postprandial glucose metabolism in five RYGB-operated individuals with PBH using a mixed meal test. All three doses prevented hypoglycemia but were associated with a notable increase in postprandial hyperglycemia. Moreover, all doses greatly diminished insulin, C-peptide, and glucagon-like peptide-1 responses. Considering its strong hyperglycemic potential, we suggest that pasireotide should be administered carefully in RYGB-operated individuals with PBH, and if necessary, a 75 μg dose seems sufficient to prevent hypoglycemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.